Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial

Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR, Clark LC

Published in BJU International

Key Findings

Selenium reduced prostate cancer incidence only in men in the lowest tertile of baseline plasma selenium, with no benefit in replete men.

Any benefit appears confined to selenium-deficient individuals.

Secondary analysis; skin cancer prevention trial population.

Mineral

Selenium reduced prostate cancer incidence only in men in the lowest tertile of baseline plasma selenium.

Year:2003

Sample Size:1,312

Duration:400 weeks

Quality Score:7/10

This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.